BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

Current stock price

1.79 USD
+0.2 (+12.58%)
Last:

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BTMD Profitability Analysis

1.1 Basic Checks

  • In the past year BTMD was profitable.
  • In the past year BTMD had a positive cash flow from operations.
  • BTMD had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 25.13%, BTMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
  • BTMD has a better Return On Invested Capital (44.85%) than 99.48% of its industry peers.
  • BTMD had an Average Return On Invested Capital over the past 3 years of 32.37%. This is significantly above the industry average of 13.10%.
  • The last Return On Invested Capital (44.85%) for BTMD is above the 3 year average (32.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROIC 44.85%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • BTMD's Profit Margin of 14.07% is amongst the best of the industry. BTMD outperforms 87.43% of its industry peers.
  • In the last couple of years the Profit Margin of BTMD has declined.
  • BTMD's Operating Margin of 18.50% is amongst the best of the industry. BTMD outperforms 86.91% of its industry peers.
  • BTMD's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BTMD (71.46%) is better than 78.53% of its industry peers.
  • BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

5

2. BTMD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
  • BTMD has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BTMD has been increased compared to 5 years ago.
  • BTMD has a better debt/assets ratio than last year.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • BTMD has an Altman-Z score of 2.57. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BTMD has a Altman-Z score of 2.57. This is in the better half of the industry: BTMD outperforms 63.87% of its industry peers.
  • The Debt to FCF ratio of BTMD is 4.43, which is a neutral value as it means it would take BTMD, 4.43 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BTMD (4.43) is better than 84.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Altman-Z 2.57
ROIC/WACC5.7
WACC7.87%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.22 indicates that BTMD should not have too much problems paying its short term obligations.
  • The Current ratio of BTMD (1.22) is worse than 81.15% of its industry peers.
  • A Quick Ratio of 0.79 indicates that BTMD may have some problems paying its short term obligations.
  • The Quick ratio of BTMD (0.79) is worse than 85.34% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 0.79
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

6

3. BTMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 277.27% over the past year.
  • Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -26.76% on average per year.
  • The Revenue for BTMD has decreased by -21.22% in the past year. This is quite bad
  • BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.51% yearly.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%

3.2 Future

  • BTMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
  • BTMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

8

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 2.16, the valuation of BTMD can be described as very cheap.
  • BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.95% of the companies in the same industry.
  • BTMD is valuated cheaply when we compare the Price/Earnings ratio to 27.18, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 5.95 indicates a rather cheap valuation of BTMD.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 95.29% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.96, BTMD is valued rather cheaply.
Industry RankSector Rank
PE 2.16
Fwd PE 5.95
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.48
EV/EBITDA 4.18
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The decent profitability rating of BTMD may justify a higher PE ratio.
  • A cheap valuation may be justified as BTMD's earnings are expected to decrease with -8.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%

0

5. BTMD Dividend Analysis

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (4/13/2026, 8:12:01 PM)

1.79

+0.2 (+12.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-05
Inst Owners63.53%
Inst Owner Change0.07%
Ins Owners9.77%
Ins Owner Change0%
Market Cap70.35M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target3.24 (81.01%)
Short Float %5.7%
Short Ratio7.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.47%
PT rev (3m)-37.68%
EPS NQ rev (1m)-13.64%
EPS NQ rev (3m)-13.64%
EPS NY rev (1m)18%
EPS NY rev (3m)14.93%
Revenue NQ rev (1m)-2.92%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-2.41%
Valuation
Industry RankSector Rank
PE 2.16
Fwd PE 5.95
P/S 0.37
P/FCF 2.48
P/OCF 2
P/B N/A
P/tB N/A
EV/EBITDA 4.18
EPS(TTM)0.83
EY46.37%
EPS(NY)0.3
Fwd EY16.81%
FCF(TTM)0.72
FCFY40.27%
OCF(TTM)0.9
OCFY50.03%
SpS4.89
BVpS-1.49
TBVpS-1.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROCE 56.77%
ROIC 44.85%
ROICexc 72.95%
ROICexgc 117.64%
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
FCFM 14.74%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Debt/EBITDA 2.57
Cap/Depr 187.03%
Cap/Sales 3.57%
Interest Coverage 4.51
Cash Conversion 89.73%
Profit Quality 104.75%
Current Ratio 1.22
Quick Ratio 0.79
Altman-Z 2.57
F-Score7
WACC7.87%
ROIC/WACC5.7
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year14.18%
EBIT Next 3Y14.95%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%

BIOTE CORP -A / BTMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 6 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


What is the profitability of BTMD stock?

BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.


What is the financial health of BIOTE CORP -A (BTMD) stock?

The financial health rating of BIOTE CORP -A (BTMD) is 5 / 10.


What is the earnings growth outlook for BIOTE CORP -A?

The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to decline by -63.75% in the next year.